Clinical trials: Stage II Skin Cancer
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by…
- Trial name
- NCT00875979
- Testing
- Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
- Where
- 20 sites in United States, Belgium and 5 more
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Uveal Melanoma
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in participants with metastatic uveal melanoma (mUM).
- Trial name
- NCT02570308
- Testing
- IMCgp100
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Immunocore Ltd
Metastatic Breast Cancer
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- NCT01207102
- Testing
- Abraxane, Carboplatin
- Where
- 2 sites in United States, China
- Volunteers
- 10 people
- Sponsor
- Duke University
Uveal Melanoma
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
- Trial name
- NCT03070392
- Testing
- IMCgp100, Dacarbazine, Ipilimumab
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 378 people
- Sponsor
- Immunocore Ltd
Recurrent Melanoma, Stage IIIB Melanoma
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body.
- Conditions
- Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT02296112
- Testing
- trametinib, laboratory biomarker analysis, pharmacological study
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Melanoma (Skin)
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage…
- Trial name
- NCT00049530
- Testing
- PEG-interferon alfa-2b
- Where
- 32 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Cancer
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
- Trial name
- CheckMate 7A8 (NCT04075604)
- Testing
- Nivolumab, Anastrozole, Palbociclib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Male Breast Cancer, Nausea and Vomiting
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy.
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00343863
- Testing
- palonosetron hydrochloride, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Breast Cancer
Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
The purpose of this pilot study is to use a pre surgical intervention model to evaluate the biologic effects of metformin in women with newly diagnosed early invasive breast cancer.
- Trial name
- NCT00930579
- Testing
- Metformin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Columbia University
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
This study is being done for the following reasons: The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1.
- Trial name
- NCT02236000
- Testing
- Neratinib, T-DM1
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- NSABP Foundation Inc
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Melanoma
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
- Trial name
- NCT01350401
- Testing
- Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Adaptimmune
Breast Cancer
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
- Trial name
- NRR (NCT00182728)
- Testing
- surgery, therapy, radiation therapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her breast and decreasing the…
- Trial name
- NCT00462865
- Testing
- Gemcitabine and Capecitabine and Avastin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Neoplasms, Breast
Brain Metastases In ErbB2-Positive Breast Cancer
This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic…
- Trial name
- NCT00437073
- Testing
- capecitabine, topotecan, lapatinib
- Where
- 44 sites in United States, Austria and 9 more
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.
- Trial name
- NCT01439711
- Testing
- letrozole, MRI, conventional surgery
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer, Breast Carcinoma
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
The purpose of this study is to examine the safety and efficacy of Ruxolitinib in combination with Trastuzumab in treatment of HER2 positive metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
- Trial name
- NCT02066532
- Testing
- Ruxolitinib, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dawn L. Hershman
Metastatic Melanoma, Skin Cancer
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Background: gp100 is a protein that is often found in melanoma tumors. An experimental procedure developed for treating patients with melanoma uses anti-gp100 cells designed to destroy their tumors.
- Trial name
- NCT00610311
- Testing
- cyclophosphamide, fludarabine phosphate, Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
The goal of this clinical research study is to learn if Tarceva® (erlotinib hydrochloride) can help control triple receptor-negative breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT00739063
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.